AR078521A1 - Compuesto pirazolotiazol - Google Patents

Compuesto pirazolotiazol

Info

Publication number
AR078521A1
AR078521A1 ARP100103603A ARP100103603A AR078521A1 AR 078521 A1 AR078521 A1 AR 078521A1 AR P100103603 A ARP100103603 A AR P100103603A AR P100103603 A ARP100103603 A AR P100103603A AR 078521 A1 AR078521 A1 AR 078521A1
Authority
AR
Argentina
Prior art keywords
group
optionally
alkyl
alkoxy
substituent
Prior art date
Application number
ARP100103603A
Other languages
English (en)
Inventor
Akira Inomata
Kodo Shikata
Taro Terauchi
Yoshinori Takahashi
Minako Hashizume
Kogyoku Shin
Kunitoshi Takeda
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR078521A1 publication Critical patent/AR078521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: Un compuesto representado por la formula (1) o su sal aceptable para uso farmacologico, caracterizado porque X es un átomo de nitrogeno o CH, R1 es -A11-A12; A11 es un enlace simple o un grupo alquileno C1-6; A12 es (a) un átomo de hidrogeno, (b) un grupo alquilo C1-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A, o (C) un grupo cicloalquilo C3-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A; R2 es -A21-A22; A21 es un enlace simple o un grupo alquileno C1-6; A22 es (a) un átomo de hidrogeno, (b) un grupo alquilo C1-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A, o (c) un grupo cicloalquilo C3-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A; (d) un grupo heterocíclico no aromático seleccionado de un grupo tetrahidropiranilo, un grupo dihidropiranilo, un grupo tetrahidrofurilo, un grupo dioxanilo, un grupo hexahidrooxepinilo, un grupo oxabiciclo[3.1.0]hexilo, un grupo tetrahidrotienilo, un grupo ditianilo, y un grupo hexahidrotiepinilo, el cual tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A, o (e) un grupo heteroarilo seleccionado del grupo piridilo, un grupo pirimidinilo, y un grupo tiazolilo; R3 es (a) un grupo alquilo C1-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A, (b) un grupo cicloalquilo C3-6, (c) un grupo alcoxi C1-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A, (d) un grupo cicloalquilo C3-6-alquilo C1-6, (d) un grupo di-alquil C1-6-amino, (f) un átomo de halogeno, (g) un grupo ciano, (h) un grupo formilo, o (i) un grupo carboxilo; R4 es un átomo de hidrogeno, o un grupo alcoxi C1-6; R5 es un átomo de halogeno, un grupo alquilo C1-6, o un grupo alcoxi C1-6; R6 es un átomo de hidrogeno, un grupo alquilo C1-6, un grupo alcoxi C1-6, un grupo alquiltio C1-6; o un grupo alquilsulfinilo C1-6; y R7 es un grupo alquilo C1-6, un grupo alcoxi C1-6, o un grupo alquiltio C1-6; con la condicion de que R3 sea (a) un grupo alquilo C1-6 opcionalmente sustituido con un grupo hidroxilo, (b) un grupo cicloalquilo C3-6, (c) un grupo alcoxi C2-6 que tiene opcionalmente 1 a 3 sustituyentes seleccionados del grupo sustituyente A, (d) un grupo alcoxi C3-6 alcoxi C1-6, (e) un grupo alcoxi C1-2 alquilo C2-6, (f) un grupo di-alquil C1-6 amino, (g) un átomo de halogeno, (h) un grupo formilo o (i) un grupo carboxilo cuando X es CH, A12 es un grupo alquilo C1-6, o un grupo cicloalquilo C3-6 que tiene opcionalmente un grupo metilo, R2 es un grupo tetrahidrofurilmetilo, un grupo tetrahidropiranilmetilo, o un grupo tetrahidropiranilo, R6 es un átomo de hidrogeno, y R7 es un grupo metoxi; y donde el grupo sustituyente A consiste de un átomo de halogeno, un grupo hidroxilo, un grupo alquilo C1-6 y un grupo alcoxi C1-6.
ARP100103603A 2009-10-08 2010-10-04 Compuesto pirazolotiazol AR078521A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24981709P 2009-10-08 2009-10-08
JP2009233989 2009-10-08
US35297010P 2010-06-09 2010-06-09
JP2010132008 2010-06-09

Publications (1)

Publication Number Publication Date
AR078521A1 true AR078521A1 (es) 2011-11-16

Family

ID=43855334

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103603A AR078521A1 (es) 2009-10-08 2010-10-04 Compuesto pirazolotiazol

Country Status (6)

Country Link
US (1) US8530504B2 (es)
EP (1) EP2487178A4 (es)
JP (1) JPWO2011043381A1 (es)
AR (1) AR078521A1 (es)
TW (1) TW201127845A (es)
WO (1) WO2011043381A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6585625B2 (ja) 2014-01-21 2019-10-02 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
KR102596307B1 (ko) * 2017-04-27 2023-10-30 바이엘 애니멀 헬스 게엠베하 새로운 비시클릭 피라졸 유도체
CN113372317B (zh) * 2020-03-09 2023-09-22 南京药石科技股份有限公司 一种四氢-2h-吡喃-3-酮的工业化生产方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5320360B2 (es) 1973-05-30 1978-06-26
EP0068378B1 (en) 1981-06-26 1986-03-05 Schering Corporation Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4596872A (en) * 1985-06-05 1986-06-24 Schering A.G. Imidazo[1,2-a]pyridines, and process for their preparation
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5190862A (en) * 1987-04-01 1993-03-02 Boehringer Mannheim Gmbh Chromogenic compounds and the use thereof as enzyme substrates
US5179103A (en) * 1987-06-15 1993-01-12 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
GB8713908D0 (en) 1987-06-15 1987-07-22 Fujisawa Pharmaceutical Co Pyrazolopyridine compound
FR2619818B1 (fr) * 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5127936A (en) * 1988-07-19 1992-07-07 E. I. Du Pont De Nemours And Company Substituted phenyltriazolopyrimidine herbicides
KR900701787A (ko) 1988-07-19 1990-12-04 제임스 제이. 플린 치환된 페닐트리아졸로피리미딘 제초제
JPH085790B2 (ja) 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
DE3942356A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh Verwendung von 1-arylsemicarbaziden zur stabilisierung von enzymsubstraten, entsprechende verfahren und diagnostisches mittel enthaltend einen solchen stabilisator
DE3942357A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel
DE3942355A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfuer geeignetes diagnostisches mittel
DE69232323T2 (de) 1991-01-29 2002-08-08 Fujisawa Pharmaceutical Co Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
FR2687675B1 (fr) * 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
DE69323883T2 (de) * 1992-06-17 1999-07-22 Upjohn Co Pyrridino-, pyrrolidino- und azepino-substituierte oxime als antiatherosklerosemittel und antihypercholesterolemiemittel
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
AU690527B2 (en) 1992-12-17 1998-04-30 Pfizer Inc. Pyrazoles having CRF antagonist activity
JP2781661B2 (ja) 1992-12-17 1998-07-30 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしての置換ピラゾール
NZ258690A (en) 1992-12-17 1997-01-29 Pfizer Pyrrolopyrimidines and pharmaceutical compositions containing such compounds; intermediate pyrrole compounds
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
FR2701708B1 (fr) 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
DE4311460A1 (de) * 1993-04-08 1994-10-13 Boehringer Mannheim Gmbh Verfahren zur kolorimetrischen Bestimmung eines Analyten mittels Benzylalkoholdehydrogenase und einem chromogenen Redoxindikator
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
FR2714059B1 (fr) 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
ATE243697T1 (de) 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivate als crf antagonisten
PL191271B1 (pl) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
PT882051E (pt) 1996-02-07 2002-04-29 Janssen Pharmaceutica Nv Tiofenopirimidinas
US6664261B2 (en) * 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
US20010007867A1 (en) * 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
WO1999010350A1 (en) 1997-08-22 1999-03-04 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
WO1999040090A1 (fr) 1998-02-04 1999-08-12 Nissan Chemical Industries, Ltd. Derives de la pyridine fusionnes avec un azole, et herbicide
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
JP3506033B2 (ja) 1999-03-09 2004-03-15 住友金属工業株式会社 熱間圧延棒鋼または線材の製造方法
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
DK1218380T3 (da) * 1999-10-08 2004-03-15 Gruenenthal Gmbh Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen
DE19948434A1 (de) * 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
SE9903760D0 (sv) * 1999-10-18 1999-10-18 Astra Ab New compounds
PL355019A1 (en) * 1999-10-08 2004-03-22 Grunenthal Gmbh Bicyclic imidazo-5-yl-amine derivatives
EP1218382B1 (de) * 1999-10-08 2004-01-28 Grünenthal GmbH Bicyclische imidazo-3-yl-aminderivate
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
JP2003516992A (ja) 1999-12-17 2003-05-20 デュポン ファーマシューティカルズ カンパニー イミダゾピリミジニル誘導体およびイミダゾピリジニル誘導体
JP2004532792A (ja) 2000-07-14 2004-10-28 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 神経障害を治療するためのイミダゾ［１，２−ａ］ピラジン
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2004531475A (ja) 2001-01-26 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー コルチコトロピン放出因子阻害剤としてのイミダゾリル誘導体
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
MXPA03009738A (es) * 2001-04-27 2004-01-29 Eisai Co Ltd Pirazol [1,5-a] piridinas y medicinas que las contienen.
JP3939548B2 (ja) 2001-12-18 2007-07-04 三菱アルミニウム株式会社 フィン用塗料組成物、フィン及びその製法並びに熱交換器
JP3939566B2 (ja) 2002-02-15 2007-07-04 三菱アルミニウム株式会社 フィン用塗料組成物、フィン及びその製造方法並びに熱交換器
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
JP2005526090A (ja) 2002-03-13 2005-09-02 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 神経伝達物質調節因子としてのピラゾロ（１，５−ａ）ピリジン誘導体
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
DE60326869D1 (de) 2002-10-22 2009-05-07 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridinverbindungen
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
WO2005079868A2 (en) 2004-02-13 2005-09-01 Sb Pharmco Puerto Rico Inc Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
JP2009233989A (ja) 2008-03-27 2009-10-15 Toppan Cosmo Inc 化粧材
CN102007133B (zh) 2008-04-15 2013-06-12 卫材R&D管理有限公司 3-苯基吡唑并[5,1-b]噻唑化合物
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
TWI358017B (en) 2009-12-17 2012-02-11 Askey Computer Corp Electronic device loading base

Also Published As

Publication number Publication date
EP2487178A4 (en) 2013-07-24
US20110086882A1 (en) 2011-04-14
JPWO2011043381A1 (ja) 2013-03-04
EP2487178A1 (en) 2012-08-15
US8530504B2 (en) 2013-09-10
WO2011043381A1 (ja) 2011-04-14
TW201127845A (en) 2011-08-16

Similar Documents

Publication Publication Date Title
AR088449A1 (es) Benzilindazoles sustituidos
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
AR076171A1 (es) Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central.
MX346367B (es) Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo.
UY32074A (es) Compuestos de pirrol
BR112012007844A2 (pt) composto heterocíclico e seu uso para controle de uma peste artrópode.
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
TR201820824T4 (tr) IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler.
ECSP10010060A (es) Derivados de pirazol sustituídos
CO6150142A2 (es) Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
AR094712A1 (es) Modificador de sabor dulce
CL2008002703A1 (es) Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios.
DE602004022404D1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
ATE510829T1 (de) Neue verbindungen als adenosin-a1-rezeptor- antagonisten
AR097866A1 (es) Derivados de 4-azaindol
MA32296B1 (fr) Derives de piperidine 3,4-substitues comme inhibiteurs de la renine
AR078521A1 (es) Compuesto pirazolotiazol
BRPI0911659B8 (pt) composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
DOP2011000296A (es) Compuesto de pirazol
DOP2009000105A (es) Derivados de pirrol, su preparación y su utilización en terapéutica
CO6190551A2 (es) Derivado de alquilsulfona
CR20110306A (es) Derivados de morfina-6-glucuronido, su preparación y su aplicación en terapéutica
DE602006010349D1 (de) Antitumorale kombination aus substituierten acryloyldistamycin-derivaten und wachstumsfaktoren oder ihre rezeptoren hemmende antikörper
BRPI0907732A2 (pt) compostos orgânicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure